Annex IV 
Conclusions on the granting of the marketing authorisation under exceptional circumstances 
presented by the European Medicines Agency 
40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions presented by the European Medicines Agency on: 
â€¢  Marketing authorisation under exceptional circumstances 
The CHMP having considered the application is of the opinion that the risk-benefit balance is 
favourable to recommend the granting of the marketing authorisation under exceptional 
circumstances as further explained in the European Public Assessment Report. 
41 
 
 
